Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Apr 2016 Reuters Investment Profile 12 $20.00

ValuEngine Rating and Forecast Report for ADMA

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

01 May 2016 ValuEngine, Inc. 11 $25.00

Thomson Reuters Stock Report - ADMA Biologics Inc (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Apr 2016 Thomson Reuters Stock Report 12 $25.00

ADMA BIOLOGICS INC (ADMA=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 Apr 2016 Pechala's Reports 2 $25.00

Wright Investors Service Comprehensive Report for Adma Biologics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

01 Apr 2016 Wright Reports 55 $75.00

ADMA: 4Q15: All eyes are on potential approval in 3Q16 for RI-002 in RSV prevention of PIDD patients

Yesterday, ADMA reported 4Q15 results with a net loss of ($4.6MM), net loss per share of ($0.44), and ~$16.8MM cash, sufficie...

24 Mar 2016 Laidlaw & Company 8 $25.00

ADMA BIOLOGICS INC (ADMA=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

14 Nov 2015 Pechala's Reports 2 $25.00

ADMA: 3Q15: Potential approval in 3Q16 for RI-002 in RSV prevention in PIDD patients

Yesterday, ADMA reported 3Q15 results with a net loss of ($5.1MM) vs. Laidlaw ($4.9MM) and the Street ($4.2MM) estimates. N...

11 Nov 2015 Laidlaw & Company 8 $25.00

ADMA: Ability to neutralize Synagis-resistant RSV and higher anti-RSV antibody titers are RI-002’s advantages

ADMA reported a pre-clinical analysis showing that RI-002 could neutralize RSV strains that are resistant to Synagis (paliviz...

05 Nov 2015 Laidlaw & Company 9 $25.00

ADMA: FDA accepted review of BLA for RI-002 in primary immune deficiency disease (PIDD) ahead of the 60 day projection

This morning, ADMA reported that the FDA has accepted the review for the BLA of RI-002 as an IVIG for the prevention of infec...

21 Sep 2015 Laidlaw & Company 8 $25.00